Literature DB >> 6162555

Impaired induction of type II interferon in tumor-bearing mice.

S Matsubara, M Suzuki, N Ishida.   

Abstract

The response of mice to type II interferon inducers such as purified protein derivative of tuberculin or OK-432 was significantly impaired after either the implantation of tumor cells or the injection of cell-free tumor ascitic fluids. Complete inhibition of type II interferon induction occurred in 3 to 5 days. This inhibitory effect persisted until the death of mice implanted with tumors or for 7 days after i.p. injection of 0.2 ml of tumor ascitic fluid. The inhibitory activity was seen even with 0.2 ml of the 10,000-fold dilution of the fluid and with its filtrate passed through a Diaflo UM-10 membrane (greater than 10,000-dalton exclusion), However, such tumor ascitic fluids did not affect the induction of type I interferon in mice by polyriboinosinic-polyribocytidylic acid or tilorone-HCl. Moreover, adjuvant-induced nontumorous ascitic fluid had no inhibitory activity. These results indicate that the in vivo induction of type II interferon is specifically impaired by tumor-mediated factor(s) with molecular weights of less than 10,000.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6162555

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors.

Authors:  H Wakasugi; K Oshimi; M Miyata; Y Morioka
Journal:  J Clin Immunol       Date:  1981-07       Impact factor: 8.317

2.  Human tumour-induced inhibition of interferon action in vitro: reversal of inhibition by beta-carotene (pro-vitamin A).

Authors:  J Rhodes; P Stokes; P Abrams
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  Serum interferon levels in patients having radiotherapy for cervical carcinoma.

Authors:  F von Rheinbaben; U D Koenig; K E Schneweis
Journal:  Arch Gynecol       Date:  1983

4.  Increased expression of human monocyte HLA-DR antigens and Fc gamma receptors in response to human interferon in vivo.

Authors:  J Rhodes; D H Jones; N M Bleehen
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.